Generic Name: luspatercept
Brand Name: TBC
Manufacturer: Celgene Inc., a Bristol Myers Squibb company
Therapeutic Area: Myelodysplastic syndromes-associated anemia
Indications: For the treatment of adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts and require red blood cell (RBC) transfusions.
Manufacturer Requested Reimbursement Criteria1: For the treatment of adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts and require red blood cell (RBC) transfusions.
Submission Type: Initial
Project Status: Pending
Call for patient/clinician input open: December 23, 2020
Call for patient/clinician input closed: February 22, 2021
Anticipated Date: January 28, 2021
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.